Efficacy of thalidomide therapy in pediatric Crohn’s disease with evidence of tuberculosis

Table 1 Clinical characteristics of all cases treated with thalidomide

Patient No.	Sex	Age at thalidomide treatment	Disease duration before thalidomide	Age at ATT treatment	Disease distribution	Extra-intestinal symptoms	TB status before ATT	ATT medications and duration	Thalidomide starting dose	Thalidomide final dose (duration)	Follow-up time (mo)	Response
1	M	2 yr 8 mo	26 mo	1 yr 3 mo	Ileocolonic	Joint lesions	AFB (+), PPD (+)	HRZ, 6 m;	2.5 mg/kg per day	- (34 m)	38 mo	Remission
								HRZEP, 6 mo
2	F	2 yr	23 mo	2 mo	Colon	Perianal abscess	AFB (+)	HRZ, 3 mo;	2.5 mg/kg per day	- (7 m)	10 mo	No response
								HR, 15 mo
3	F	2 yr 4 mo	28 mo	7 mo	Colon	Perianal abscess	AFB (+)	HRZ, 9 mo;	2 mg/kg per day	0.33 mg/kg per day	33 mo	Response
								HREP, 27 mo
4	F	11 yr 7 mo	42 mo	8 yr 1 mo	Ileocolonic	Perianal skin tag	AFB (+)	HREZ, 12 mo	1.8 mg/kg per day	0.8 mg/kg per day	15 mo	Response
5	M	12 yr 6 mo	18 mo	11 yr 3 mo	Ileocolonic	Oral ulcers	TB culture (+),	HRS, 5 mo;	2 mg/kg per day	0.5 mg/kg per day	36 mo	Remission
							Spleen TB	HRE, 12 mo
6	M	12 yr 5 mo	20 mo	11 yr 5 mo	Ileocolonic	Anal fistula	AFB (+)	HRZ, 12 mo	1.2 mg/kg per day	0.6 mg/kg per day	12 mo	Remission
7	M	8 yr 6 mo	38 mo	5 yr 4 mo	Ileal	Pleural and ascetic fluid	PPD (+)	HRE, 3 mo;	2 mg/kg per day	- (44 m)	44 mo	Remission
								HRZ, 12 mo
8	F	3 yr 8 mo	16 mo	2 yr 4 mo	Ileocolonic	-	AFB (+)	HRZ, 14 mo;	2 mg/kg per day	1.6 mg/kg per day	16 mo	Response
								HRE, 12 mo
9	F	2 yr 4 mo	16 mo	1 yr	Ileocolonic	Anal fissure	AFB (+)	HRZ, 14 mo	2.2 mg/kg per day	1.8 mg/kg per day	9 mo	Remission
10	F	13 yr 6 mo	17 mo	12 yr 1 mo	Ileocolonic	Perianal skin tag	AFB (+)	HREZ, 3 mo;	1.8 mg/kg per day	1.3 mg/kg per day	9 mo	Remission
								HR, 15 mo

ATT: Anti-tubercular treatment; H: Isoniazid; R: Rifampicin; Z: Pyrazinamide; E: Ethambutol; S: Streptomycin; P: Para-aminosalicylic acid.

Table 2 Dose changes at different time points after thalidomide treatment

Patient No.	Dose (mg/kg per day) at different follow-up time (mo)
1	2.5 (baseline) - 2.5 (1 mo) - 1.2 (12 mo) - discontinue (34 mo)
2	2.5 (baseline) - discontinue (7 mo)
3	2 (baseline) - 1.1 (12 mo) - 0.7(18 mo) - 0.4 (21 mo) - 0.33 (33 mo)
4	1.8 (baseline) - 3 (5 mo) - 1 (12 mo) - 0.8 (15 mo)
5	2 (baseline) - 0.5 (2 mo) - 1.8(9 mo) - discontinue (22 mo) - 0.5 (36 mo)
6	1.2 (baseline) - 0.6 (12 mo)
7	2 (baseline) - 1.8 (1 mo) - 1.1 (10 mo) – stop (44 mo)
8	2 (baseline) – 2.4 (10 mo) - 1.6 (16 mo)
9	2.2 (baseline) -1.4 (5 mo) - 1.8 (9 mo)
10	1.8 (baseline) -1.3 (9 mo)